Erudio Healtherudio.com
Sponsor
ECOG-ACRIN Cancer Research Group trials: what clinicians said in public
An HCP commentary report on 1 clinical trial sponsored by ECOG-ACRIN Cancer Research Group: EQUATE. It covers what clinicians said in public about one trial, on podcasts, videos and posts, every statement linked to its source. Below them, 15 more trials with public commentary and no report yet.
Listed by lead sponsor as registered on ClinicalTrials.gov (ECOG-ACRIN Cancer Research Group; Eastern Cooperative Oncology Group). A trial led by a partner or a research group is on that sponsor's page. Only trials with public clinician commentary found are listed, not every trial the sponsor runs.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| EQUATE NCT04566328 · ECOG-ACRIN Cancer Research Group | newly diagnosed multiple myeloma | Phase 3 | 352 | 101 | Focused | Oct 18, 2026 | Preview |
| No report yetTrials with public commentary we haven't built a report for. Size is an estimate of the verified statements the commentary we've indexed so far will yield; final coverage is set when we build the report, within 24 hours of your confirmed order. You never pay more than quoted: a report delivered at a smaller size costs that size's price. Some can also be requested as a free preview. | |||||||
| DETER-SMM NCT03937635 · ECOG-ACRIN Cancer Research Group DeepView → | high-risk smoldering myeloma | Phase 3 | Deep | View | |||
| ENDURANCE NCT01863550 · ECOG-ACRIN Cancer Research Group DeepView → | newly diagnosed symptomatic multiple myeloma | Phase 3 | Deep | View | |||
| CHAARTED NCT00309985 · ECOG-ACRIN Cancer Research Group DeepView → | metastatic hormone-sensitive prostate cancer | Phase 3 | Deep | View | |||
| PUMP NCT05863195 · ECOG-ACRIN Cancer Research Group DeepView → | unresectable colorectal liver metastases | Phase 3 | Deep | View | |||
| CompassHER2 pCR NCT04266249 · ECOG-ACRIN Cancer Research Group DeepView → | stage II–IIIA HER2-positive breast cancer | Phase 2 | Deep | View | |||
| EA4151 NCT03267433 · ECOG-ACRIN Cancer Research Group DeepView → | Not given | Phase 3 | Deep | View | |||
| EAA241 NCT07085728 · Eastern Cooperative Oncology Group DeepView → | newly diagnosed multiple myeloma with LCCN | Phase 2 | Deep | View | |||
| E3311 NCT01898494 · ECOG-ACRIN Cancer Research Group DeepView → | p16+ locally advanced oropharynx cancer | Phase 2 | Deep | View | |||
| E2211 NCT01824875 · ECOG-ACRIN Cancer Research Group DeepView → | advanced pancreatic neuroendocrine tumors | Phase 2 | Deep | View | |||
| EA4181 NCT04115631 · ECOG-ACRIN Cancer Research Group StandardView → | untreated mantle cell lymphoma | Phase 2 | Standard | View | |||
| EA2183 NCT04248452 · ECOG-ACRIN Cancer Research Group StandardView → | oligometastatic HER2-negative esophageal and gastric adenocarcinoma | Phase 3 | Standard | View | |||
| EA1131 NCT02445391 · ECOG-ACRIN Cancer Research Group StandardView → | residual triple-negative breast cancer following neoadjuvant chemotherapy | Phase 3 | Standard | View | |||
| OPT-IN NCT04559139 · ECOG-ACRIN Cancer Research Group StandardView → | incidental gallbladder cancer | Phase 2/Phase 3 | Standard | View | |||
| E2496 NCT00003389 · Eastern Cooperative Oncology Group StandardView → | locally extensive and advanced-stage Hodgkin lymphoma | Phase 3 | Standard | View | |||
| INDICATE NCT04423211 · ECOG-ACRIN Cancer Research Group FocusedView → | Not given | Phase 3 | Focused | View | |||